cilostazol and iloprost

cilostazol has been researched along with iloprost in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (28.57)	18.2507
2000's	1 (14.29)	29.6817
2010's	3 (42.86)	24.3611
2020's	1 (14.29)	2.80

Authors

Authors	Studies
Onaya, T; Shindo, H; Tawata, M	1
Priollet, P	1
Adderley, S; Bowles, EA; Hanson, MS; Sprague, RS; Sridharan, M; Stephenson, AH	1
Adderley, SP; Bowles, EA; Ellsworth, ML; Sprague, RS; Sridharan, M; Stephenson, AH	1
Claus, PL; Domecq, JP; Elraiyah, T; Firwana, B; Hasan, R; Hingorani, A; Murad, MH; Nabhan, M; Prokop, L; Prutsky, G; Steinkraus, LW; Tsapas, A	1
Anastasiadou, C; Galyfos, G; Geropapas, G; Giannakakis, S; Kastrisios, G; Kerasidis, S; Maltezos, C; Papacharalampous, G; Papapetrou, A; Sachmpazidis, I	1
Abosheasha, MA; El-Gowily, AH	1

Reviews

2 review(s) available for cilostazol and iloprost

Article	Year
[Arteriopathy of the lower limbs: toward a global medical care]. La Revue de medecine interne, 1999, Volume: 20, Issue:6 Topics: Angiography; Arterial Occlusive Diseases; Arteriosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Endothelial Growth Factors; Genetic Therapy; Humans; Iloprost; Leg; Lymphokines; Multicenter Studies as Topic; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Protein Isoforms; Randomized Controlled Trials as Topic; Tetrazoles; Ticlopidine; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vasodilator Agents	1999
A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers. Journal of vascular surgery, 2016, Volume: 63, Issue:2 Suppl Topics: Aged; Cilostazol; Diabetic Foot; Female; Humans; Hyperbaric Oxygenation; Iloprost; Male; Middle Aged; Pentoxifylline; Tetrazoles; Treatment Outcome; Vasodilator Agents	2016

Article

Year

[Arteriopathy of the lower limbs: toward a global medical care].

La Revue de medecine interne, 1999, Volume: 20, Issue:6

Topics: Angiography; Arterial Occlusive Diseases; Arteriosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Endothelial Growth Factors; Genetic Therapy; Humans; Iloprost; Leg; Lymphokines; Multicenter Studies as Topic; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Protein Isoforms; Randomized Controlled Trials as Topic; Tetrazoles; Ticlopidine; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vasodilator Agents

1999

A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers.

Journal of vascular surgery, 2016, Volume: 63, Issue:2 Suppl

Topics: Aged; Cilostazol; Diabetic Foot; Female; Humans; Hyperbaric Oxygenation; Iloprost; Male; Middle Aged; Pentoxifylline; Tetrazoles; Treatment Outcome; Vasodilator Agents

2016

Other Studies

5 other study(ies) available for cilostazol and iloprost

Article	Year
Cyclic adenosine 3',5'-monophosphate enhances sodium, potassium-adenosine triphosphatase activity in the sciatic nerve of streptozotocin-induced diabetic rats. Endocrinology, 1993, Volume: 132, Issue:2 Topics: 1-Methyl-3-isobutylxanthine; Animals; Bucladesine; Cilostazol; Cyclic AMP; Diabetes Mellitus, Experimental; Iloprost; In Vitro Techniques; Inositol; Kinetics; Male; Myelin Sheath; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Reference Values; Sciatic Nerve; Sodium-Potassium-Exchanging ATPase; Tetrazoles	1993
Phosphodiesterase 3 is present in rabbit and human erythrocytes and its inhibition potentiates iloprost-induced increases in cAMP. American journal of physiology. Heart and circulatory physiology, 2008, Volume: 295, Issue:2 Topics: Adult; Aged; Animals; Blotting, Western; Cilostazol; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclic Nucleotide Phosphodiesterases, Type 3; Drug Interactions; Erythrocyte Membrane; Female; Humans; Iloprost; Male; Middle Aged; Milrinone; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Quinolones; Rabbits; Tetrazoles; Up-Regulation	2008
Inhibition of ATP release from erythrocytes: a role for EPACs and PKC. Microcirculation (New York, N.Y. : 1994), 2011, Volume: 18, Issue:2 Topics: Adenine; Adenosine Triphosphate; Cilostazol; Colforsin; Cyclic AMP; Enzyme Activation; Erythrocytes; Guanine Nucleotide Exchange Factors; Humans; Iloprost; In Vitro Techniques; Isoproterenol; Models, Biological; Naphthalenes; Phosphodiesterase Inhibitors; Protein Kinase C; Rolipram; Signal Transduction; Tetradecanoylphorbol Acetate; Tetrazoles; Thionucleotides	2011
Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia. VASA. Zeitschrift fur Gefasskrankheiten, 2017, Volume: 46, Issue:6 Topics: Adult; Amputation, Surgical; Ankle Brachial Index; Anticoagulants; Arteritis; Aspirin; Cardiovascular Agents; Cilostazol; Critical Illness; Drug Therapy, Combination; Female; Heparin, Low-Molecular-Weight; Humans; Iloprost; Infusions, Intravenous; Ischemia; Limb Salvage; Lower Extremity; Male; Marijuana Abuse; Marijuana Smoking; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Smoking; Smoking Cessation; Tetrazoles; Thromboangiitis Obliterans; Time Factors; Treatment Outcome; Vasodilator Agents	2017
Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 M Drug development research, 2021, Volume: 82, Issue:2 Topics: Cilostazol; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Drug Approval; Drug Evaluation, Preclinical; Drug Repositioning; Eicosapentaenoic Acid; Epoprostenol; Humans; Iloprost; Molecular Docking Simulation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; SARS-CoV-2; Spike Glycoprotein, Coronavirus; United States; United States Food and Drug Administration	2021